Literature DB >> 22975727

The stereotypy-inducing effects of N-substituted benztropine analogs alone and in combination with cocaine do not account for their blockade of cocaine self-administration.

Libin Li1, Takato Hiranita, Shuichiro Hayashi, Amy H Newman, Jonathan L Katz.   

Abstract

RATIONALE: Previous studies have demonstrated that several N-substituted 4', 4″-diF-benztropine (BZT) analogs with high dopamine transporter affinity selectively decreased cocaine self-administration without affecting food-maintained behavior in rats.
OBJECTIVES: The present study examined if the decreases in cocaine self-administration are due to competition from excess behavioral activity (hyperlocomotion or stereotypy) induced by the BZT analogs alone or in combination with cocaine.
RESULTS: Pretreatments with the typical dopamine uptake inhibitor methylphenidate [1.0, 3.2, and 10 mg/kg, intraperitoneally (i.p.)] dose-dependently shifted the cocaine self-administration dose-effect curve (0, 0.032, 0.1, 0.32, and 1.0 mg/kg/injection) leftward. The shift in the dose-effect curve was obtained at doses of methylphenidate that, when administered alone, also decreased food-maintained behavior and increased locomotor activity and stereotypy. In contrast, the N-substituted BZT analogs, JHW 007 (1.0, 3.2, and 10 mg/kg, i.p.), AHN 1-055 (10 mg/kg), and, AHN 2-005 (10 mg/kg), as previously reported, decreased the maximum for the cocaine self-administration dose-effect curve, and did so at doses that were virtually without effects on food-maintained behavior. Further, the BZT analogs alone had minimal effects on locomotor activity and stereotypies and did not appreciably change the effects of cocaine on these measures when administered in combination with cocaine.
CONCLUSIONS: The present results suggest that the decrease in cocaine self-administration produced by the N-substituted BZT analogs is due to an antagonism of the reinforcing effects of cocaine rather than due to interference from competing behavioral overstimulation, and further supports the development of N-substituted BZT analogs as medications to treat cocaine abuse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975727      PMCID: PMC4472487          DOI: 10.1007/s00213-012-2862-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter.

Authors:  G E Agoston; J H Wu; S Izenwasser; C George; J Katz; R H Kline; A H Newman
Journal:  J Med Chem       Date:  1997-12-19       Impact factor: 7.446

Review 2.  Relations between heterogeneity of dopamine transporter binding and function and the behavioral pharmacology of cocaine.

Authors:  J L Katz; A H Newman; S Izenwasser
Journal:  Pharmacol Biochem Behav       Date:  1997-07       Impact factor: 3.533

3.  Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine.

Authors:  Rajeev I Desai; Theresa A Kopajtic; Mikhail Koffarnus; Amy Hauck Newman; Jonathan L Katz
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

4.  Place conditioning and locomotor effects of N-substituted, 4',4''-difluorobenztropine analogs in rats.

Authors:  Su-Min Li; Amy Hauck Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2005-03-02       Impact factor: 4.030

5.  The dopamine uptake inhibitor 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward.

Authors:  Clara Velázquez-Sánchez; Antonio Ferragud; Vicente Hernández-Rabaza; Amparo Nácher; Virginia Merino; Miguel Cardá; Juan Murga; Juan J Canales
Journal:  Neuropsychopharmacology       Date:  2009-07-15       Impact factor: 7.853

6.  Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter.

Authors:  J V Ferrer; J A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors.

Authors:  Claus J Loland; Rajeev I Desai; Mu-Fa Zou; Jianjing Cao; Peter Grundt; Klaus Gerstbrein; Harald H Sitte; Amy Hauck Newman; Jonathan L Katz; Ulrik Gether
Journal:  Mol Pharmacol       Date:  2007-10-31       Impact factor: 4.436

8.  Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors.

Authors:  Takato Hiranita; Paul L Soto; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-02-19       Impact factor: 4.030

9.  Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity.

Authors:  Gianluigi Tanda; Amy Hauck Newman; Aaron L Ebbs; Valeria Tronci; Jennifer L Green; Ronald J Tallarida; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-05-29       Impact factor: 4.030

10.  Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine.

Authors:  Su-Min Li; Bettye L Campbell; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2006-02-14       Impact factor: 4.030

View more
  12 in total

1.  σ Receptor Effects of N-Substituted Benztropine Analogs: Implications for Antagonism of Cocaine Self-Administration.

Authors:  Takato Hiranita; Weimin C Hong; Theresa Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2017-04-25       Impact factor: 4.030

2.  Dopamine Transporter Dynamics of N-Substituted Benztropine Analogs with Atypical Behavioral Effects.

Authors:  Weimin C Hong; Michael J Wasko; Derek S Wilkinson; Takato Hiranita; Libin Li; Shuichiro Hayashi; David B Snell; Jeffry D Madura; Christopher K Surratt; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2018-06-26       Impact factor: 4.030

3.  Novel multifunctional pharmacology of lobinaline, the major alkaloid from Lobelia cardinalis.

Authors:  Dustin P Brown; Dennis T Rogers; Francois Pomerleau; Kirin B Siripurapu; Manish Kulshrestha; Greg A Gerhardt; John M Littleton
Journal:  Fitoterapia       Date:  2016-04-20       Impact factor: 2.882

4.  Cocaine Antagonists; Studies on Cocaine Self-Administration.

Authors:  Takato Hiranita
Journal:  J Alcohol Drug Depend       Date:  2015-09-03

5.  Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons.

Authors:  Alicia J Avelar; Jianjing Cao; Amy Hauck Newman; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

6.  Behavioral economic analysis of the effects of N-substituted benztropine analogs on cocaine self-administration in rats.

Authors:  Claudio Zanettini; Derek S Wilkinson; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2017-09-21       Impact factor: 4.530

7.  Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist.

Authors:  Rajeev I Desai; David K Grandy; Carl R Lupica; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

8.  Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats.

Authors:  Takato Hiranita; Stephen J Kohut; Paul L Soto; Gianluigi Tanda; Theresa A Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

9.  Blockade of Cocaine or σ Receptor Agonist Self Administration by Subtype-Selective σ Receptor Antagonists.

Authors:  Jonathan L Katz; Takato Hiranita; Theresa A Kopajtic; Kenner C Rice; Christophe Mesangeau; Sanju Narayanan; Ahmed H Abdelazeem; Christopher R McCurdy
Journal:  J Pharmacol Exp Ther       Date:  2016-04-21       Impact factor: 4.030

10.  2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter.

Authors:  Takato Hiranita; Derek S Wilkinson; Weimin C Hong; Mu-Fa Zou; Theresa A Kopajtic; Paul L Soto; Carl R Lupica; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2014-02-11       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.